Right now, because it's not coordinated—recently there's even been a new body to study the cancer drugs. There are many more layers, and then even if one is recommended, it's not mandatory that the drug plans respect it, so it's all over the map.
I think one of the recommendations you had was for the conditional listing for new medications, right? That would at least deal with the ones that are approved by Health Canada. Is that one of the recommendations?